Compare Constellation Energy Corporation (CEG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs TG Therapeutics Inc — how do they compare? Constellation Energy Corporation trades at $279.54 (market cap $98.63B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Constellation Energy Corporation is far larger — about 12.9× TG Therapeutics Inc's market cap, and Constellation Energy Corporation pays a 0.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CEG | TGTX | |
|---|---|---|
Market Cap | $98.63B | $7.64B |
Sector | Energy | Health |
52-Week High | $403.95 | $59.06 |
52-Week Low | $236.50 | $26.94 |
Enterprise Value | $122.63B | $7.84B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CEG trades at $278.68, up 3.05% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and Calpine integration. Revenue growth is robust, with 2026 projections at $31.3B, and profitability metrics like ROE of 15.26% highlight efficient capital use.
The stock offers upside to the consensus price target of $332.13, with 70% of analysts rating it Buy. Key risks include execution of growth initiatives and market volatility, but strong cash flow and strategic positioning in AI-driven power demand support a positive outlook for investors.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
